2 weeks Ago By ABMN Staff
Rhumbline Advisers raised its stake in shares of Invivyd, Inc. ( NASDAQ:IVVD – Free Report ) by 4,434.1% during the 2nd quarter, according to the company in its most recent filing with the SEC.
The firm owned 84,017 shares of the company’s stock after purchasing an additional 82,164 shares during the quarter. Rhumbline Advisers’ holdings in Invivyd were worth $92,000 as of its most recent filing with the SEC. Several other institutional investors also recently modified their holdings of the company.
Vanguard Group Inc. increased its position in shares of Invivyd by 3.9% during the 1st quarter.
Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after purchasing an additional 97,496 shares in the last quarter. Jacobs Levy Equity Management Inc.
grew its stake in Invivyd by 21.7% during the first quarter. Jacobs Levy Equity Management Inc.
now owns 435,338 shares of the company’s stock worth $1,933,000 after buying an additional 77,603 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Invivyd during the second quarter worth about $263,000. Acadian Asset Management LLC acquired a new stake in shares of Invivyd during the first quarter worth approximately $905,000.
Finally, Chase Investment Counsel Corp acquired a new position in Invivyd during the 1st quarter worth about $271,000. Institutional investors and hedge funds own 70.36% of the company’s stock.
Analyst Ratings Changes Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Invivyd in a research note on Tuesday, September 3rd. Invivyd Price Performance NASDAQ:IVVD opened at $1.
02 on Tuesday. The business’s 50-day simple moving average is $1.05 and its 200-day simple moving average is $1.
79. Invivyd, Inc. has a fifty-two week low of $0.
81 and a fifty-two week high of $5.20. The stock has a market capitalization of $121.
70 million, a PE ratio of -0.55 and a beta of 0.61.
Invivyd ( NASDAQ:IVVD – Get Free Report ) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.
37) by ($0.03). The firm had revenue of $2.
26 million for the quarter, compared to the consensus estimate of $4.91 million. On average, research analysts expect that Invivyd, Inc.
will post -0.6 earnings per share for the current year. Invivyd Profile ( Free Report ) Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Further Reading Want to see what other hedge funds are holding IVVD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invivyd, Inc.
( NASDAQ:IVVD – Free Report ). Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter .
.
